Table 2.
Significant Predictors and Moderators of Remission with Monotherapy by 12 Weeks of Treatments: Results from Cox Survival Regression Models
| HR (95% CI) | ||||
|---|---|---|---|---|
| Main effect | Interaction with treatment | Interaction with site | Interaction with treatment and site | |
| PAS-SR | ||||
| Panic symptoms | .76 (.63–.92) | |||
| Drug phobia | .79 (.64–.96) | |||
| Fear of losing control/depersonalization | .75 (.63–.91) | |||
| Agoraphobia | .82 (.68–1.00) | |||
| Medical reassurance | .59(.39–.91) | 2.35 (1.00–5.51) | ||
| Loss sensitivity | 2.29 (1.08–4.86) | |||
| Separation anxiety | 2.33 (1.09–5.01) | |||
| MOODS-SR (depressive component) | ||||
| Depressive mood | .74 (.62–.89) | |||
| Suicidality | .77 (.64–.93) | |||
| Psychomotor retardation | .69 (.58–.82) | |||
| Neurovegetative symptoms | .84 (.70–1.00) | |||
| Psychotic features | .82 (.68–.98) | |||
| MOODS-SR (manic/hypomania component) | ||||
| Psychomotor activation | .70 (.49–1.00) | |||
| Total SHY | .76 (.63–.91) | |||
| Baseline HDRS-17 | .74 (.61–.91) | |||
| Baseline HDRS-25 | .68 (.56–.83) | |||
| Marital status (married) | 1.69 (1.19–2.39) | |||
| WSAS | .56 (.46–.68) | |||
| Hypersomnia HDRS | .65 (.52–.81) | 2.58 (1.64−4.07) | ||
| Any anxiety disorder | .69 (.48–.99) | |||